Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation

<div>CD326−CD133+ EVs-related survival analysis. (a) The Kaplan–Meier survival curves for the overall cancer population (<i>n</i> = 104) were calculated on the basis of the peripheral blood concentrations of CD326-CD133 + EVs. (b) The Kaplan–Meier survival curves for lung cancer patients (<i>n</i> = 51) were calculated on the basis of the peripheral blood concentration of CD326-CD133 + EVs.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 